标题
Targeting the PD-1 pathway: a promising future for the treatment of melanoma
作者
关键词
Nivolumab, MK-3475, Ipilimumab, PD-1, PD-L1, Programmed cell death receptor 1, Immunotherapy, Melanoma, BRAF
出版物
ARCHIVES OF DERMATOLOGICAL RESEARCH
Volume 306, Issue 6, Pages 511-519
出版商
Springer Nature
发表日期
2014-03-10
DOI
10.1007/s00403-014-1457-7
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer
- (2013) C. Zielinski et al. ANNALS OF ONCOLOGY
- Clinical characteristics and outcomes with specificBRAFandNRASmutations in patients with metastatic melanoma
- (2013) Amanda D. Bucheit et al. CANCER
- Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types
- (2013) P. A. Ascierto et al. CLINICAL CANCER RESEARCH
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
- (2013) D. T. Frederick et al. CLINICAL CANCER RESEARCH
- The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures
- (2013) Jérôme Galon et al. IMMUNITY
- Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma
- (2013) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment
- (2013) Paolo A Ascierto et al. Journal of Translational Medicine
- New checkpoint inhibitors ride the immunotherapy tsunami
- (2013) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapy for metastatic melanoma: the past, present, and future
- (2012) Laura Finn et al. BMC Medicine
- When Progressive Disease Does Not Mean Treatment Failure: Reconsidering the Criteria for Progression
- (2012) G. R. Oxnard et al. JNCI-Journal of the National Cancer Institute
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
- (2011) James S. Wilmott et al. CLINICAL CANCER RESEARCH
- Cancer Immunotherapy Comes of Age
- (2011) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation